Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy

Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy
Shahin Hallaj,^1,* Fatemeh Meshkini,²
1. Immunology research center, Tabriz university of medical sciences
2. Immunology research center, Tabriz university of medical sciences
Introduction: Cancer immunotherapy aims to enhance the immune system reactivity against tumour cells. Chimeric Antigen Receptor (CAR), presented on the surface of the T cells, specifically redirects the cell and demonstrates sig- nificant promises in treating patients with different types of haematologic malignancies.
Methods: Although several cases of improvement have been reported, clinical experiences, such as excessive activity, poor control, toxicity and limited life span of conventional CAR T cells have emerged as treatment challenges associated with this therapeutic strategy. Recently, multiple switchable CAR T platforms have been made to enable better control in a dose-dependent manner, which is correlated to distinct characteristics of different switch molecules.
Results: This review aimed at a brief represention of toxicities of the CAR T cells, the obstacles facing tumour treatments especially in solid tumours, and finally providing a framework for classification of the newly de- veloped Conjugated/Split CAR-T cell technologies to overcome difficulties.
Conclusion: Overall, Newly developed Conjugated CAR T cells using among with soluble switch molecules seems to be as responsive as the conven- tional CAR T cells, yet providing many new useful options to effectively overcome limitations and significantly improve patient safety.
Keywords: Adaptable CAR T Cell Conjugated CAR T Cell Split CAR T Cell Universal Car T Cell